Home
overview
Setting the right price and ensuring that the product is adequately reimbursed is vital for a company's profitability. Pricing and reimbursement is one of the most complicated and important business issues that the pharmaceuticals industry has to deal with. In response to ever increasing cost containment; pressures, pricing regulations and reimbursement trends are continually changing.

SMi’s inaugral conference will provide a forum for senior European Pricing & Reimbursement decision-makers to learn about pricing structures and practices in North America.

The current ways and procedures hinder the European Pharma Industry in accessing the North American Market.

The objectives of this event are to highlight key elements of pharmaceutical pricing in the US and Canada. We will evaluate what the recent Medicare reform means for European manufacturers. Will it open up a new market offering fresh opportunities and challenges? We will determine the price discrepancy for prescription drugs between international and North American markets as well as cross-border purchasing and the effects it has on Canadian drug supply.

This is a great opportunity to learn from leading industry experts including:

  • Marc Benoff, US Practice Leader, Pricing & Market Access, Cambridge Pharma Consultancy (a unit of IMS Health)
  • Dr Sanjay Gupta, Senior Director & Head, Global Health Outcomes, Millennium Pharmaceuticals
  • Dr Robert Freeman, Senior Director, Public Policy, AstraZeneca
  • Anita Burrell, Director, Global Health Economics, Aventis
  • Dr Kathy Feegel, Director, State Government Affairs, Amgen
  • Dillard Howell, Director, Global Product Protection, Eli Lilly
  • Ted Bittner, Senior Director, Marketing, Altana Pharma US
  • Michael Wang, Director, Pricing & Reimbursement, Celgene Corporation
  • Kathleen Hughes, Vice President & Director, Consulting Operations, Covance
  • Donald Zowader, Manager, Government Affairs, Takeda Pharmaceuticals North America
  • Paul Doulton, Managing Partner, Oriundo

Key issues that will be addressed:

PRICING & REIMBURSEMENT: Discover the current and evolving trends in North America
US ELECTION CYCLES: Understand their impact on coverage, reimbursement and pricing policies
MEDICARE & MEDICAID: Gain an insight into the recent advances and what the future holds for both programmes
PRICING AND REIMBURSEMENT STRATEGIES: Assess the importance of formulating and implementing a coherent pricing strategy and the challenges of targeting multiple therapeutics
MAXIMISING MARKET ACCESS IN CANADA: Hear about the strategic position of the Canadian market
INTERNET PHARMACIES: Learn about dispensing drugs over the Internet and assess the impact on industry
KEY INDUSTRY PERSONNEL: Meet the leaders in the field, learn from their experiences and make valuable contacts

Conference programme

9:00 Chairman's Opening Remarks

Marc Benoff

Marc Benoff, US Practice Leader, Pricing and Market Access, IMS Consulting

9:10 PHARMACEUTICAL PRICING AND REIMBURSEMENT IN NORTH AMERICA

Marc Benoff

Marc Benoff, US Practice Leader, Pricing and Market Access, IMS Consulting

  • The current pricing environment and common strategies
  • The key stakeholders within the market
  • Pricing and reimbursement structure
  • Pricing discounts
  • Reimbursement
  • Potential future US market access/pricing scenarios
  • 9:50 REIMPORTATION AND PARALLEL TRADE IN NORTH AMERICA

    Stefan Szymanski

    Stefan Szymanski, FT MBA Programme Director, Imperial College London

  • The concept of exhaustion of intellectual property rights
  • The conflict between competition law and IP law
  • What is good for consumers: uniform prices or international price discrimination?
  • What does this mean for pharmaceutical companies?
  • 10:30 Morning Coffee

    11:00 PARALLEL IMPORTS

    Kathy Feegel

    Kathy Feegel, Director, State Government Relations, Amgen

  • Supply chain risks and patient safety
  • Overview of federal and state legislation – current status of importation programmes
  • Information on municipal level programmes
  • Exemptions for specific products
  • Politics driving policy?
  • The need to address the broader issues of the healthcare system
  • Industry and other stakeholders’ positions
  • Price controls and the effect on innovation
  • 11:40 US ELECTION CYCLES

    Robert Freeman

    Robert Freeman, Senior Director, Public Policy, AstraZeneca

  • Legislative and regulatory initiatives in the context of policy and politics
  • The private sector/public sector interface and their impact on federal policy
  • What to expect in the US political environment
  • Reference pricing
  • Parallel trade vs reimportation
  • Reimbursement and coverage policy initiatives
  • 12:20 Networking Lunch

    14:00 MEDICARE DRUG BENEFIT

    Mason Tenaglia

    Mason Tenaglia, Vice President, Charles River Associates Inc

  • What is it? how does it work?
  • How might it evolve?
  • What does it mean for pharmaceutical marketing?
  • 14:40 MEDICAID

    Donald Zowader

    Donald Zowader, Manager, Government Affairs, Takeda Pharmaceuticals North America

  • How did we (the US) get here?
  • Rebates and preferred drug lists - why and how?
  • Whats next - 2006 and ???
  • 15:20 WHAT DOES THE RECENT MEDICARE REFORM MEAN FOR EUROPEAN MANUFACTURERS...

    Jim Furniss

    Jim Furniss, Director, Pricing & Reimbursement, Bridgehead International

  • New challenges, opportunities and risks for pharmaceutical companies
  • Challenging long held business models
  • Forming the right partnerships and alliances
  • Managing risk
  • Capturing market share
  • Securing reimbursement
  • 16:00 Chairman's Closing Remarks

    9:00 Chairman's Opening Remarks

    Stefan Szymanski

    Stefan Szymanski, FT MBA Programme Director, Imperial College London

    Stefan Szymanski

    Stefan Szymanski, FT MBA Programme Director, Imperial College London

    9:10 GETTING YOUR FACTS RIGHT

  • Valid information about how the market perceives your product is critical to pricing it successfully at the launch
  • The information needed for effective US pricing decisions, however, is not always what one might expect
  • Getting the right information means
  • using the right processes
  • tapping the right data sources
  • leveraging the right analytical methods
  • This presentation will provide some unconventional perspectives on how to do each of these steps right for the US market
  • Michael Wang

    Michael Wang, Director, Pricing & Reimbursement, Celgene

    Boris Simkovich

    Boris Simkovich, President, Light Management Consulting

    9:50 THE ROLE OF HEALTH ECONOMIC/OUTCOMES IN PRICING AND REIMBURSEMENT

    Sanjay Gupta

    Sanjay Gupta, Senior Director & Head, Global Health Outcomes, Millennium Pharmaceuticals

  • Healthcare industry macro trends and implications for drug companies
  • Establishing pricing ranges using health economic models
  • Assessing multiple inputs used for development of optimal price
  • Health outcomes data and tools to justify price and ensure reimbursement
  • 10:30 Morning Coffee

    11:00 DEVELOPING SUCCESSFUL PRICING AND REIMBURSEMENT STRATEGIES

    Kathleen Hughes

    Kathleen Hughes, Vice President & Director, Consulting Operations, Covance

  • Assessment of clinical and pharmacoeconomic outcomes
  • - Independent vs those of competitors

  • Determination of product position
  • - Evaluating new and existing services (pricing, reimbursement and other perspectives)

  • Formulation of a coherent pricing strategy
  • Understanding of coverage, coding and reimbursement issues and determination of strategies and tactics to deal with them:
  • - Medicare, Medicaid and private payment methods

    - Differences in payment depending on site of service, payer and payment methods

  • Consideration of alternative indications:
  • - The challenges of targeting multiple therapeutics

  • Case histories
  • 11:40 PRICE DISCREPANCIES FOR PRESCRIPTION DRUGS

  • Economic framework for differential prices
  • Why do prices differ and does it matter?
  • Pitfalls in international comparisons
  • Looking to the future
  • Anita Burrell

    Anita Burrell, Director, Global Health Economcs , Aventis Pharmaceuticals

    Martin Egler

    Martin Egler, Senior Manager, Health System and P & R Intelligence, Sanofi-Aventis

    12:20 Networking Lunch

    14:40 MAXIMISING MARKET ACCESS IN CANADA

    Neil Palmer

    Neil Palmer, Principle Consultant, Palmer D'Angelo

  • The key elements of pharmaceutical pricing and price regulation in Canada
  • The Canadian reimbursement market – who are the major stakeholders?
  • Optimal reimbursement strategies to maximise market access
  • The latest developments and impact of cross border trade from Canada to US
  • Outlook for pricing and reimbursement in Canada – implications for other markets
  • 15:20 WHICH WAY LATIN AMERICA?

    Paul Doulton

    Paul Doulton, Managing Partner, Oriundo

  • Where is healthcare heading in Mexico?
  • Mexico - who pays now and who in the future?
  • Where is healthcare heading in Latin America?
  • How should the pharmaceutical industry respond?
  • 16:00 Chairman's Closing Remarks

    +

    Thistle Victoria

    Buckingham Palace Road
    London SW1W 0SJ
    United Kingdom

    Thistle Victoria

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.